INDSWFTLAB

Ind-Swift Laboratories Ltd.

330.20-6.5 (-1.95%)
19 Nov, 12:00 AM

Income Statement

Abridged
Understanding Income Statement
Ind-Swift Laboratories Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.
2012
Mar 31
2013
Mar 31
2014
Mar 31
2015
Mar 31
2016
Mar 31
R
2017
Mar 31
R
2018
Mar 31
R
2019
Mar 31
2020
Mar 31
2021
Mar 31
C
2022
Mar 31
2023
Mar 31
2024
Mar 31
2025
Mar 31
2026
Mar 31
TTM
Sep 30
Period length:
Source:
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
IR
Total Revenue
1,4091,1369656606537167657577808911,0391,2071,281562649776
Cost of Operating Revenue
1,1911,015865492406465480557498558745807803347356354
Gross Profit
218121100169248251285200282333293400478214293421
Gross Margin
15.510.710.425.637.935.037.326.436.237.428.233.137.338.245.254.3
Total Operating Expenses
1,2711,1331,0056586307047187127067809601,0271,066603633687
Operating Profit
1383-393241247447411179180215-421688
Operating Margin
9.80.3-4.10.43.61.76.25.99.512.47.614.916.8-7.42.511.4
Financing Income/(Expense) - Net
-72-136-113-117-106-88-28-81-93-96-80-68-2246540
Profit before Taxes
87-119-142-143-83-553650-2018138758225851106
Income Taxes
-3-1-20-24-24-16142112115391607821
Profit after Tax
89-118-122-119-59-392229-21-3-2484212504385
PAT Margin
6.3-10.4-12.6-18.1-9.0-5.52.93.8-2.7-0.4-0.23.932.944.66.611.0
EPS - Basic - ex Extraordinary Items
24.86-30.09-29.79-29.14-14.33-9.204.886.19-4.28-0.53-0.368.0671.2437.255.169.82
EPS - Diluted - ex Extraordinary Items
23.98-30.09-29.79-29.14-14.33-9.204.885.30-4.28-0.53-0.368.0671.2435.215.039.76
EBIT
1383-393241247447411179180215-421688
EBITDA
186714289108101134149164198210238268-1747121
EBITDA Margin
13.26.34.313.516.614.117.519.621.022.220.219.720.9-3.17.215.5

Balance Sheet

Abridged
Understanding Balance Sheet
Ind-Swift Laboratories Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.
2012
Mar 31
C
2013
Mar 31
R
2014
Mar 31
R
2015
Mar 31
R
2016
Mar 31
R
2017
Mar 31
R
2018
Mar 31
R
2019
Mar 31
2020
Mar 31
2021
Mar 31
R
2022
Mar 31
2023
Mar 31
2024
Mar 31
2025
Mar 31
2026
Mar 31
Source:
AR
AR
AR
AR
AR
AR
AR
AR
AR
AR
AR
AR
AR
AR
AR
Total Current Assets
9951,0239899208668328858368639441,0751,165661865977
Long-Term Investments
11717182626272828563536113178241
Property Plant & Equipment - Net
9321,2301,2149779328938648458017486375935260287
Total Non-Current Assets
1,2231,5311,5621,3241,3531,3061,1811,0881,007874725660504573697
Total Assets
2,2182,3742,3202,2442,2192,1382,0661,9241,8701,8181,8011,8241,1651,4381,673
Total Current Liabilities
6186636308331,0121,005983356323315334371221221257
Long Term Debt
711818964816684592520966891885848753112612
Total Non-Current Liabilities
1,0771,2801,3551,2661,1441,007534980906901865771124532
Total Liabilities
1,6951,9431,9852,0992,1562,0121,5171,3361,2291,2151,2001,142234265289
Total Shareholders' Equity
8248537255955175315495886416046016829311,1731,384
Minority Interest
---------00-000
Total Equity
8248537255955175315495886416036016829311,1731,384
Total Liabilities & Equity
2,5202,7962,7112,6942,6732,5432,0661,9241,8701,8181,8011,8241,1651,4381,673

Cash Flow

Abridged
Understanding Cash Flow Statement
Ind-Swift Laboratories Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.
2012
Mar 31
2013
Mar 31
2014
Mar 31
2015
Mar 31
2016
Mar 31
R
2017
Mar 31
2018
Mar 31
R
2019
Mar 31
2020
Mar 31
2021
Mar 31
2022
Mar 31
2023
Mar 31
2024
Mar 31
R
2025
Mar 31
2026
Mar 31
Period length:
Source:
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
12M
AR
Operating CF bef Changes in Working Cap
111.11-11.405.4450.46101.98112.61124.6190.9189.32114.61133.89117.95212.26-12.3385.21
Working Capital - Increase/(Decrease)
-112.63-136.3822.88-23.35-63.08-19.1921.410.19-29.04-61.18-86.59-36.63-489.90-19.76-103.37
Net CF from Operating Activities
-1.52-147.7828.3227.1138.9093.42146.0291.1060.2853.4347.2981.32-277.65-32.08-18.15
Capital Expenditures - Net
178.8554.0530.8739.0330.1632.0821.1014.9210.794.4012.9212.6341.5725.8186.53
Net CF from Investing Activities
-216.43-51.97-30.83-39.17-30.27-31.86-21.25-15.17-9.69-10.684.21-13.90-122.69-151.64-128.17
Dividends Paid - Cash - Total
3.42--------------
Stock - Issuance/(Retirement) - Net
3.721.32-----------92.63162.98
Debt - LT & ST - Issuance/(Retirement) - Total
193.69152.92-6.428.88-13.20-66.35-131.61-53.69-67.71-41.72-37.33-71.83-103.3920.99-15.07
Net Cash Flow from Financing Activities
211.86170.642.8911.13-6.68-65.83-131.07-53.17-67.71-41.72-37.33-71.83831.82114.33147.29
Free Cash Flow to Equity
13.32-48.92-8.96-3.05-4.46-5.01-6.6822.49-18.237.32-2.96-3.13-422.61-36.90-119.76
Free Operating CF net dividend
-184.12-202.10-2.64-12.133.3661.31124.8675.6649.1149.0328.8868.55-322.16-96.49-105.88
Free Operating CF
-180.70-202.10-2.64-12.133.3661.31124.8675.6649.1149.0328.8868.55-322.16-96.49-105.88

Business Segment Analysis

FY End:
Mar 26

Ind-Swift Laboratories Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex
Total₹ 88Cr
Bulk Drugs & Pharmaceuticals (100.0%)₹ 87.72 Cr
Revenue / Sales
Total₹ 649Cr
Bulk Drugs & Pharmaceuticals (100.0%)₹ 649.14 Cr
Assets
Total₹ 1,673Cr
Bulk Drugs & Pharmaceuticals (100.0%)₹ 1,673.35 Cr
Operating Income
Total₹ 16Cr
Bulk Drugs & Pharmaceuticals (100.0%)₹ 16.20 Cr

Regional Segment Analysis

FY End:
Mar 26

Ind-Swift Laboratories Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales
Total₹ 613Cr
Other Foreign (79.1%)₹ 484.39 CrIndia (20.9%)₹ 128.24 Cr

Historical Segment Analysis

Track how Ind-Swift Laboratories Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Business
2019
Mar 31
2020
Mar 31
2021
Mar 31
2022
Mar 31
2023
Mar 31
2024
Mar 31
2025
Mar 31
2026
Mar 31
Bulk Drugs & Pharmaceuticals151141813456488

Frequently Asked Questions

What is the revenue of Ind-Swift Laboratories Ltd.?
The latest trailing twelve month revenue of Ind-Swift Laboratories Ltd. is ₹ 775.67 Cr, reflecting a 1-year growth of -5.63% and a 3-year CAGR of -13.94%. Annual and quarterly revenue trends are available in the Income Statement section.
What is the net profit of Ind-Swift Laboratories Ltd.?
The latest trailing twelve month net profit (PAT) of Ind-Swift Laboratories Ltd. is ₹ 85.19 Cr, with a 3-year earnings CAGR of 3.98%. Detailed profit history across annual and quarterly periods is in the Income Statement section.
What is the EBITDA of Ind-Swift Laboratories Ltd.?
The trailing twelve month EBITDA of Ind-Swift Laboratories Ltd. is approximately ₹ 17.53 Cr (based on an operating margin of 2.26%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.
What is the EPS of Ind-Swift Laboratories Ltd.?
The trailing twelve month Earnings Per Share (EPS) of Ind-Swift Laboratories Ltd. is 9.76. EPS trends across annual and quarterly periods are visible in the Income Statement section.
What is the debt level of Ind-Swift Laboratories Ltd.?
The debt-to-equity ratio of Ind-Swift Laboratories Ltd. stands at 1.04. The interest coverage ratio is 10.31x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.
What is the book value per share of Ind-Swift Laboratories Ltd.?
The estimated book value per share of Ind-Swift Laboratories Ltd. is 169.54 (derived from a P/B ratio of 1.95 and market price of ₹ 330.20), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.
What is the cash flow from operations of Ind-Swift Laboratories Ltd.?
The trailing twelve month operating cash flow of Ind-Swift Laboratories Ltd. is ₹ -52.14 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.
Does Ind-Swift Laboratories Ltd. report consolidated or standalone financials?
Ind-Swift Laboratories Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.